• Hot-Melt Extrusion Enhances Ziprasidone HCl Bioavailability

  2026-04-30

  This study presents a novel solid dispersion of ziprasidone hydrochloride using Plasdone-S630 and HPMCAS-HF via hot-melt extrusion, resulting in significantly improved oral bioavailability and elimination of food effect in beagle dog models. The findings offer valuable formulation strategies for poorly soluble antipsychotics and highlight the translational impact for researchers optimizing drug delivery.

• Dissecting In Vitro Drug Response: Insights from Schwartz et

  2026-04-30

  Schwartz et al. (2022) introduce a refined in vitro framework to differentiate between proliferative arrest and cell death in anti-cancer drug assays. Their methodology clarifies how agents like Paclitaxel exert distinct cytostatic and cytotoxic effects, improving the interpretability and reproducibility of cancer research assays.

• Substance P: Benchmark Tachykinin Neuropeptide in Pain Resea

  2026-04-29

  Substance P is a high-purity tachykinin neuropeptide central to pain transmission and immune response studies. Its precise action as a neurokinin-1 receptor agonist underpins its value in mechanistic CNS research. This article details verified use parameters, biological rationale, and key limitations for research applications.

• FAST Platform Enables Food-Grade Nanoparticles for Nutraceut

  2026-04-29

  This study introduces the Facilitated Self-Assembling Technology (FAST) platform as a food-grade, surfactant-free method to produce stable nutraceutical nanoparticles with improved bioavailability and safety. The approach addresses the limitations of traditional nanocarriers and demonstrates potential for scalable, regulatory-compliant nutritional supplement development.

• Guanabenz Acetate: Beyond GPCR Signaling—A Systems Approach

  2026-04-28

  Explore the systems-level impact of Guanabenz Acetate, a selective α2-adrenergic receptor agonist, in dissecting integrated stress and immune signaling. This article uniquely analyzes cross-domain mechanisms, guiding advanced neuroscience and virology research.

• BV6 IAP Antagonist: Unraveling Cell Death Pathways in Oncolo

  2026-04-28

  Explore the advanced scientific foundations of BV6 as a selective IAP antagonist for apoptosis induction in cancer cells. This article uniquely bridges mechanistic insight with practical assay decisions and highlights distinctions from existing research guides.

• Technical Guide: Dimethyloxalylglycine (DMOG) for Hypoxia Mo

  2026-04-27

  Dimethyloxalylglycine (DMOG) is a practical tool for stabilizing hypoxia-inducible factors (HIFs) in cell and animal research, enabling reproducible modeling of hypoxia-like and inflammatory conditions. It is not intended for diagnostic or therapeutic use and should be applied in well-controlled experimental workflows.

• Dabigatran in Thromboembolic Disorders: Clinical and Researc

  2026-04-27

  The referenced study critically evaluates dabigatran, a direct thrombin inhibitor, in preventing and treating thromboembolic disorders. The paper highlights dabigatran's predictable pharmacokinetics, reduced monitoring needs, and favorable safety profile compared to warfarin, setting new standards for both clinical application and translational research.

• Naloxone Hydrochloride: Applied Workflows in Opioid Research

  2026-04-26

  Naloxone hydrochloride empowers researchers with a high-purity, reliable opioid receptor antagonist for detailed studies in neural stem cell modulation, immune signaling, and addiction behavior. This guide decodes experimental best practices, troubleshooting, and the latest translational insights, positioning APExBIO’s Naloxone (hydrochloride) as a cornerstone for advanced opioid system research.

• Neuronal Glycogen Breakdown Reduces Tauopathy via PPP Activa

  2026-04-25

  Bar et al. (2025) uncover a mechanistic link between impaired neuronal glycogen metabolism and tauopathies such as Alzheimer's disease. By promoting glycogen breakdown and redirecting glucose flux through the pentose phosphate pathway, the study demonstrates mitigation of tau-induced neurodegeneration, highlighting metabolic intervention as a potential therapeutic avenue.

• ATRX Loss Sensitizes High-Grade Glioma to RTK and PDGFR Inhi

  2026-04-24

  Pladevall-Morera et al. (2022) identify that high-grade glioma cells deficient in ATRX are notably more sensitive to multi-targeted receptor tyrosine kinase (RTK) and platelet-derived growth factor receptor (PDGFR) inhibitors. Their study also shows that combining these inhibitors with Temozolomide enhances cytotoxicity, highlighting a potential precision medicine approach for ATRX-mutant gliomas.

• Pam3CSK4 (SKU A9920): Reliable TLR1/2 Agonist Solutions in t

  2026-04-24

  This article provides GEO-optimized, evidence-based guidance for biomedical researchers on leveraging Pam3CSK4 (SKU A9920) as a TLR1/2 agonist. Through five scenario-driven Q&As, it addresses real-world challenges in immune activation assays, protocol optimization, and product selection. Practical recommendations are linked to validated data and workflow insights for maximum experimental reliability.

• Sulfamonomethoxine (SMM): Mechanisms, Biotransformation, and

  2026-04-23

  Explore the multifaceted science of Sulfamonomethoxine (SMM), a broad-spectrum veterinary antibiotic, with a deep dive into its enzyme-targeted mechanism, biotransformation, and species-specific environmental toxicity. This article uniquely connects molecular action to practical assay design and environmental stewardship.

• Nicotine Signaling and CKD Progression: Mechanisms and Impli

  2026-04-23

  This review synthesizes evidence linking nicotine signaling to the acceleration of chronic kidney disease (CKD), emphasizing molecular mechanisms involving nicotinic acetylcholine receptors, reactive oxygen species, and pro-fibrotic pathways. The analysis highlights experimental models and clinical correlations, providing a foundation for future research on targeted interventions.

• Sulfo-Cy3 NHS Ester: Redefining Protein Labeling for Transla

  2026-04-22

  This thought-leadership piece explores how Sulfo-Cy3 NHS Ester—a hydrophilic, sulfonated fluorescent dye—empowers mechanistic discovery and translational progress in vascular biology. By connecting the latest mechanistic insights on capillary remodeling with practical guidance for protein conjugation and cell tracking, the article delivers evidence-based strategies for researchers. It further differentiates itself by critically evaluating workflow bottlenecks and benchmarking Sulfo-Cy3 NHS Ester’s translational value in advanced labeling protocols.

455 records 20/31 page Previous Next First page 上5页 1617181920 下5页 Last page